AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29701801 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower estimated glomerular filtration rate
Number of subjects: 1718
Study 29701801 — intervention group
Group type: EXPERIMENTAL
Intervention: Low vs. high adherence to antihypertensive medication
Number of subjects: 1718
Study 29701801 — intervention group
Group type: EXPERIMENTAL
Intervention: Pakistan vs. Sri Lanka
Number of subjects: 1718
Study 29701801 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐reported kidney disease
Number of subjects: 1718
Study 29701801 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving vs. not receiving statins
Number of subjects: 1718
Study 25939394 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-use supplementary food (RUSF)
Number of subjects: 81
Study 25939394 — intervention group
Group type: COMPARATOR
Intervention: Improved corn-soya blend (CSB+)
Number of subjects: 81
Study 24937648 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated intervention group
Number of subjects: 1247
Study 24937648 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted intervention group
Number of subjects: 1247
Study 24937648 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigated intervention group
Number of subjects: 1247
Study 24937648 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior CRCS
Number of subjects: 1247
Study 24937648 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior CRCS at baseline
Number of subjects: 1247
Study 24937648 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 1247
Study 22433221 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (DTX) alone, 75 mg/m², 8 cycles, every 3 weeks
Number of subjects: 300
Study 22433221 — intervention group
Group type: COMPARATOR
Intervention: Other treatment groups (combined)
Number of subjects: 300
Study 22433221 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (DTX)
Number of subjects: 300
Study 22433221 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (PTX)
Number of subjects: 300
Study 19281469 — intervention group
Group type: EXPERIMENTAL
Intervention: tolterodine-ER (4 mg once daily)
Number of subjects: 0
Study 19281469 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 17449504 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice given by pharmacists during consultations
Number of subjects: 0
Study 15608401 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominant hand of right-handed subjects
Number of subjects: 60
Study 15608401 — intervention group
Group type: COMPARATOR
Intervention: Non-dominant hand of right-handed subjects
Number of subjects: 60
Study 15608401 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominant hand of left-handed subjects
Number of subjects: 60
Study 15608401 — intervention group
Group type: COMPARATOR
Intervention: Non-dominant hand of left-handed subjects
Number of subjects: 60
Study 11269754 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin T measurement
Number of subjects: 91
Study 11269754 — intervention group
Group type: COMPARATOR
Intervention: Case control group
Number of subjects: 91
Study 11269754 — intervention group
Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 91
Study 9738131 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet (4.19‐5.44 MJ or 1,200‐1,300 kcal/day)
Number of subjects: 91
Study 9738131 — intervention group
Group type: COMPARATOR
Intervention: Exercise (five 45‐min sessions at 78.5+/‐0.5% maximum heart rate)
Number of subjects: 91
Study 9738131 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and Diet (ED)
Number of subjects: 91
Study 9738131 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 91
Study 9738131 — intervention group
Group type: COMPARATOR
Intervention: Exercise (E)
Number of subjects: 91
Study 9738131 — intervention group
Group type: COMPARATOR
Intervention: Diet (D)
Number of subjects: 91
Study 8066309 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (120-240 mg/day)
Number of subjects: 31
Study 8066309 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (10-20 mg/day)
Number of subjects: 31
Study 8066309 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 31
Study 3276167 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure reduction of 26.2 mmHg (standard error = 13.4)
Number of subjects: 10053
Study 3276167 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure reduction of 10.0 mmHg (standard error = 5.3)
Number of subjects: 10053
Study 3276167 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure reduction
Number of subjects: 10053
Study 3276167 — intervention group
Group type: COMPARATOR
Intervention: Systolic blood pressure reduction
Number of subjects: 10053
Study 31955237 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-radius posterior-stabilized mobile-bearing TKA
Number of subjects: 22
Study 30056395 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group A (primer letter/leaflet and a self‐referral letter)
Number of subjects: 0
Study 30056395 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group B (primer letter/leaflet and a patient navigation call)
Number of subjects: 0
Study 30056395 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care; no input from GP practice)
Number of subjects: 0
Study 27465872 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison of groups
Number of subjects: 133
Study 24909376 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio-recorded information on compact disc (CD) during medical consultation
Number of subjects: 130
Study 24909376 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard information without audio recording)
Number of subjects: 130
Study 21351188 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 21351188 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 0
Study 21351188 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 21351188 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients (Tamoxifen and Exemestane)
Number of subjects: 0
Study 21351188 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive test performance
Number of subjects: 0
Study 20398941 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 397
Study 20398941 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 397
Study 20398941 — intervention group
Group type: COMPARATOR
Intervention: Sham injections
Number of subjects: 397
Study 18570193 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based treatment
Number of subjects: 80
Study 18570193 — intervention group
Group type: COMPARATOR
Intervention: Individual supportive psychotherapy
Number of subjects: 80
Study 16116010 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block with 0.375% bupivacaine and 5 microg/mL epinephrine
Number of subjects: 80
Study 16116010 — intervention group
Group type: COMPARATOR
Intervention: Control group (no femoral nerve block)
Number of subjects: 80
Study 16116010 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block with epidural analgesia
Number of subjects: 80
Study 12364634 — intervention group
Group type: EXPERIMENTAL
Intervention: 5x300 mg 4162W94 (cohort 1 and 2)
Number of subjects: 48
Study 12364634 — intervention group
Group type: EXPERIMENTAL
Intervention: 5x100 mg 4162W94
Number of subjects: 48
Study 12364634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 12364634 — intervention group
Group type: EXPERIMENTAL
Intervention: 5x300 mg 4162W94
Number of subjects: 48
Study 8763896 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Number of subjects: 10703
Study 8763896 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic cell sensitisers
Number of subjects: 10703
Study 8763896 — intervention group
Group type: EXPERIMENTAL
Intervention: ARCON (accelerated radiotherapy, carbogen and nicotinamide)
Number of subjects: 10703
Study 8763896 — intervention group
Group type: COMPARATOR
Intervention: Overall from meta-analysis
Number of subjects: 10703
Study 2272136 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexabrix (ionic low osmolar heparinized contrast media)
Number of subjects: 500
Study 2272136 — intervention group
Group type: EXPERIMENTAL
Intervention: Isovue (nonionic low osmolar heparinized contrast media)
Number of subjects: 500
Study 2272136 — intervention group
Group type: COMPARATOR
Intervention: Hexabrix
Number of subjects: 500
Study 2272136 — intervention group
Group type: COMPARATOR
Intervention: Isovue
Number of subjects: 500
Study 2272136 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Hexabrix and Isovue
Number of subjects: 500
Study 7204712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0
Study 7204712 — intervention group
Group type: COMPARATOR
Intervention: Antihistaminic classic
Number of subjects: 0
Study 7204712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31125101 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular group (app + accelerometer)
Number of subjects: 210
Study 31125101 — intervention group
Group type: EXPERIMENTAL
Intervention: Plus group (app + accelerometer)
Number of subjects: 210
Study 31125101 — intervention group
Group type: COMPARATOR
Intervention: Combined regular and plus groups
Number of subjects: 210
Study 31125101 — intervention group
Group type: COMPARATOR
Intervention: Control group (accelerometer only)
Number of subjects: 210
Study 28953776 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine + Acetylsalicylic Acid (100 mg)
Number of subjects: 40
Study 28953776 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram + Placebo
Number of subjects: 40
Study 26364885 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with instructions about restricting food and fluid intake prior to radiotherapy simulation and treatment
Number of subjects: 20
Study 26364885 — intervention group
Group type: COMPARATOR
Intervention: Patients without instructions about restricting food and fluid intake prior to radiotherapy simulation and treatment
Number of subjects: 20
Study 26364885 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings regarding the need for adaptive radiotherapy
Number of subjects: 20
Study 23407470 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal swab samples
Number of subjects: 4000
Study 23407470 — intervention group
Group type: COMPARATOR
Intervention: Other specimen types (endocervical swabs or urine)
Number of subjects: 4000
Study 21247431 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 5 mg/kg intravenous bolus injection, followed by 1.5 mg/kg/h continuous intravenous infusion until 3 hours after cessation of CPB
Number of subjects: 28
Study 21247431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 21247431 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 28
Study 19140906 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial rate‐adaptive pacing (AAIR)
Number of subjects: 10
Study 19140906 — intervention group
Group type: COMPARATOR
Intervention: Ventricular demand pacing (VVI)
Number of subjects: 10
Study 17524595 — intervention group
Group type: EXPERIMENTAL
Intervention: Storytelling educational intervention (ST)
Number of subjects: 64
Study 17524595 — intervention group
Group type: COMPARATOR
Intervention: Numeric risk tool intervention (NR)
Number of subjects: 64
Study 14760966 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-year-old man
Number of subjects: 95
Study 14760966 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-year-old man
Number of subjects: 95
Study 14760966 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-year-old man
Number of subjects: 95
Study 14760966 — intervention group
Group type: EXPERIMENTAL
Intervention: Murder
Number of subjects: 95
Study 14760966 — intervention group
Group type: COMPARATOR
Intervention: Theft
Number of subjects: 95
Study 11522155 — intervention group
Group type: EXPERIMENTAL
Intervention: Sun protection education provided to aquatic staff at intervention pools.
Number of subjects: 220
Study 11522155 — intervention group
Group type: COMPARATOR
Intervention: Education on child injury prevention provided to aquatic staff at control pools.
Number of subjects: 220
Study 9920070 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 microg DSG orally daily and 100 mg T enanthate, i.m., weekly
Number of subjects: 24
Study 9920070 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 microg DSG and 50 mg T enanthate
Number of subjects: 24
Study 9920070 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 microg DSG and 100 mg T enanthate
Number of subjects: 24
Study 9920070 — intervention group
Group type: EXPERIMENTAL
Intervention: DSG (300 or 150 microg daily) alone for the first 3 weeks
Number of subjects: 24
Study 9920070 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of T enanthate (50 and 100 mg weekly)
Number of subjects: 24
Study 9920070 — intervention group
Group type: EXPERIMENTAL
Intervention: DSG alone
Number of subjects: 24
Study 7703390 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant erythropoietin (EPO)
Number of subjects: 152
Study 7703390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 2641393 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125 mg of triazolam administered sublingually
Number of subjects: 40
Study 2641393 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactulose solution 66.7%)
Number of subjects: 40
Study 19949 — intervention group
Group type: EXPERIMENTAL
Intervention: EHDP (20 mg kg‐1 day‐1)
Number of subjects: 19
Study 19949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 31390674 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized surgeon letter with surgical information, surgeon picture, and surgeon signature
Number of subjects: 281
Study 31390674 — intervention group
Group type: COMPARATOR
Intervention: Control group received the same letter a month later
Number of subjects: 281
Study 31967979 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiostimulation (PBS) after implant surgery
Number of subjects: 60
Study 31967979 — intervention group
Group type: COMPARATOR
Intervention: Placebo (simulated photobiostimulation) after implant surgery
Number of subjects: 60
Study 31967979 — intervention group
Group type: COMPARATOR
Intervention: Control (implant surgery only)
Number of subjects: 60
Study 30146166 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly high-dose vitamin D3 supplementation (100,000 IU)
Number of subjects: 5108
Study 30146166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5108
Study 28595182 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplements containing 125 mg green tea, 25 mg capsaicin and 50 mg ginger extracts
Number of subjects: 50
Study 28595182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 25593284 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 45
Study 25593284 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control (CON)
Number of subjects: 45
Study 23886127 — intervention group
Group type: EXPERIMENTAL
Intervention: Specially designed tobacco control program including anti-tobacco awareness classes, formation of anti-tobacco task forces, inter-school competitions, supplying IEC materials, and providing a handbook on tobacco control for school personnel.
Number of subjects: 4144
Study 21817821 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10mg/day) plus a statin
Number of subjects: 171
Study 21817821 — intervention group
Group type: COMPARATOR
Intervention: Double dose of statin
Number of subjects: 171
Study 19243207 — intervention group
Group type: EXPERIMENTAL
Intervention: Fed state (CER 30 mg)
Number of subjects: 16
Study 19243207 — intervention group
Group type: COMPARATOR
Intervention: Fasted state (CER 30 mg)
Number of subjects: 16
Study 16886114 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 106
Study 16886114 — intervention group
Group type: COMPARATOR
Intervention: Parenteral Nutrition (PN)
Number of subjects: 106
Study 14715180 — intervention group
Group type: EXPERIMENTAL
Intervention: Azimilide dihydrochloride 35 mg
Number of subjects: 172
Study 14715180 — intervention group
Group type: EXPERIMENTAL
Intervention: Azimilide dihydrochloride 75 mg
Number of subjects: 172
Study 14715180 — intervention group
Group type: EXPERIMENTAL
Intervention: Azimilide dihydrochloride 125 mg
Number of subjects: 172
Study 14715180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 11710578 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac after oral administration
Number of subjects: 10
Study 11710578 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac after rectal administration
Number of subjects: 10
Study 11710578 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (internal standard)
Number of subjects: 10
Study 9275110 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 448
Study 7733220 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based prevention program (modified classroom teacher practices, parent training, child social skills training)
Number of subjects: 0
Study 2646315 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (50 micrograms, subcutaneously)
Number of subjects: 20
Study 2646315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31829111 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost prompt group (Picture Option Grid DA with cost discussion prompt)
Number of subjects: 311
Study 31829111 — intervention group
Group type: COMPARATOR
Intervention: Non-cost prompt groups (text‐only Option Grid DA and usual care)
Number of subjects: 311
Study 31829111 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost prompt group
Number of subjects: 311
Study 31829111 — intervention group
Group type: COMPARATOR
Intervention: Non-cost prompt groups
Number of subjects: 311
Study 30325567 — intervention group
Group type: EXPERIMENTAL
Intervention: FTC/TAF 200/10 mg + darunavir (DRV) 800 mg + ritonavir (RTV) 100 mg (treatment A)
Number of subjects: 0
Study 30325567 — intervention group
Group type: EXPERIMENTAL
Intervention: FTC/TAF 200/25 mg alone (treatment C)
Number of subjects: 0
Study 30325567 — intervention group
Group type: EXPERIMENTAL
Intervention: DRV/cobicistat (COBI) 800/150 mg (treatment B)
Number of subjects: 0
Study 30325567 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30325567 — intervention group
Group type: EXPERIMENTAL
Intervention: RTV and COBI boosting effects on TAF bioavailability
Number of subjects: 0
Study 28609567 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1021958 (60 mg single dose)
Number of subjects: 140
Study 28609567 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1021958 (≥60 mg single doses)
Number of subjects: 140
Study 28609567 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1021958 (>40 mg multiple doses)
Number of subjects: 140
Study 28609567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 25146413 — intervention group
Group type: EXPERIMENTAL
Intervention: Live delivery (LD)
Number of subjects: 118
Study 25146413 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine delivery (TD)
Number of subjects: 118
Study 25146413 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WL)
Number of subjects: 118
Study 24089234 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative frozen section (IFS) performed, n=66
Number of subjects: 80
Study 24089234 — intervention group
Group type: COMPARATOR
Intervention: No intraoperative frozen section (IFS) performed, n=14
Number of subjects: 80
Study 21217530 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care and exercise (UC + EX) group performed a comprehensive prehabilitation program including resistance training using bands, flexibility, and step training at least 3 times per week for 4‐8 weeks before TKA.
Number of subjects: 71
Study 21217530 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) group maintained normal daily activities before TKA.
Number of subjects: 71
Study 19949272 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin K (K(1) and K(2)) supplementation
Number of subjects: 50
Study 19949272 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin K(2) supplementation
Number of subjects: 50
Study 19949272 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 50
Study 17044661 — intervention group
Group type: EXPERIMENTAL
Intervention: Efonidipine (40 mg)
Number of subjects: 5
Study 17044661 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine (2 mg)
Number of subjects: 5
Study 17044661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 15149751 — intervention group
Group type: EXPERIMENTAL
Intervention: Permixon 320 mg/day
Number of subjects: 124
Study 15149751 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.4 mg/day
Number of subjects: 124
Study 11181371 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha(1)-acid glycoprotein (AAG) concentrations
Number of subjects: 0
Study 11181371 — intervention group
Group type: COMPARATOR
Intervention: Black subjects
Number of subjects: 0
Study 11181371 — intervention group
Group type: EXPERIMENTAL
Intervention: Unbound or free amprenavir concentrations
Number of subjects: 0
Study 9490088 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy protocols
Number of subjects: 4455
Study 8282435 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator
Number of subjects: 352
Study 8282435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study 2959900 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized fenoterol plus ipratropium bromide
Number of subjects: 79
Study 2959900 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol
Number of subjects: 79
Study 2959900 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol plus steroids
Number of subjects: 79
Study 2959900 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline, IV, plus steroids and oral fenoterol
Number of subjects: 79